Our programs Medical research and healthcare
Cancer research
Our programs Medical research and healthcare
Cancer research
Understanding cancer better for a better outcome
An aging population, changes in our lifestyle and environmental risks all contribute to the increase in cancer cases. With 157,000 deaths in 2018, cancer remains the leading cause of death in France. Despite the progress achieved over the past few years as regards diagnosis and treatment, this disease remains the leading cause of death in France, to which 157,000 succumbed in France in 2018. Right now, the pandemic raises the specter of an increase in the number of late diagnoses and a poorer health outcome for patients, due to deferred treatment. However, recovery is now possible for 57% of cancers in women, and 44% of cancers in men.
Too many patients are still faced with treatment failure. How can we better understand the processes that govern the development of cancer? Why have some care protocols proved successful in certain cancers and certain patients but not in others? What are the resistance mechanisms that come into play, and how can we neutralize them? This is one of Fondation de France’s key battles.
The Oncology Treatment Resistance program is one of some 15 projects being run each year, amounting to two million euros.
Contact
The program team
A question? Need more details on our action for this cause? Send an email to the program team.
Understanding cancer better for a better outcome
An aging population, changes in our lifestyle and environmental risks all contribute to the increase in cancer cases. With 157,000 deaths in 2018, cancer remains the leading cause of death in France. Despite the progress achieved over the past few years as regards diagnosis and treatment, this disease remains the leading cause of death in France, to which 157,000 succumbed in France in 2018. Right now, the pandemic raises the specter of an increase in the number of late diagnoses and a poorer health outcome for patients, due to deferred treatment. However, recovery is now possible for 57% of cancers in women, and 44% of cancers in men.
Too many patients are still faced with treatment failure. How can we better understand the processes that govern the development of cancer? Why have some care protocols proved successful in certain cancers and certain patients but not in others? What are the resistance mechanisms that come into play, and how can we neutralize them? This is one of Fondation de France’s key battles.
The Oncology Treatment Resistance program is one of some 15 projects being run each year, amounting to two million euros.
Contact
The program team
A question? Need more details on our action for this cause? Send an email to the program team.
Call for projects
Fondation de France studies the issue of resistance to cancer treatment. It also allocates grants to physicians and pharmacists for their first international assignment.
Cancer – a study of treatment resistance
Fondation de France supports fundamental and translational research on resistance to treatment in malignant hematological disorders and solid tumors.
Call for projects
Fondation de France studies the issue of resistance to cancer treatment. It also allocates grants to physicians and pharmacists for their first international assignment.
Cancer – a study of treatment resistance
Fondation de France supports fundamental and translational research on resistance to treatment in malignant hematological disorders and solid tumors.
